Clinical Trials
24
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
First-trimester Placental Ultrasound Study
- Conditions
- Fetal Growth ComplicationsPregnancy Complications
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 4000
- Registration Number
- NCT05326191
- Locations
- 🇬🇧
King's College Hospital NHS, Fetal Medicine Foundation, London, United Kingdom
Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple Organ Application
- Conditions
- Multiple
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 200
- Registration Number
- NCT05110248
- Locations
- 🇬🇧
Gemini One, 5520 John Smith Drive, Oxford, Oxfordshire, United Kingdom
UK Imaging Diabetes Study Seeing Diabetes Clearly
- Conditions
- Type2 Diabetes
- First Posted Date
- 2021-09-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 1000
- Registration Number
- NCT05057403
- Locations
- 🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom
Contrast-Free Magnetic Resonance Imaging for Breast Disease
- Conditions
- Breast CancerBreast Diseases
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 1030
- Registration Number
- NCT05006196
- Locations
- 🇬🇧
Gemini One, Oxford, United Kingdom
West Hertfordshire Inflammatory Bowel Disease Technology Study
- Conditions
- Inflammatory Bowel Diseases
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Perspectum
- Target Recruit Count
- 200
- Registration Number
- NCT05000242
- Locations
- 🇬🇧
West Hertfordhsire Teaching Hospitals NHS Trust, Watford, Hertfordshire, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Landmark Study Confirms Liver Health Biomarker cT1 Predicts Cardiac and Liver Outcomes
A major Nature Medicine study of 28,841 individuals demonstrates that Perspectum's iron corrected T1 (cT1) MRI biomarker effectively predicts both liver-related and cardiac outcomes, establishing it as a valuable non-invasive alternative to liver biopsy.
MRI Biomarkers Show Promise in Predicting Treatment Response in MASH, Reducing Need for Biopsies
• New research validates quantitative MRI imaging as a reliable alternative to liver biopsies for assessing disease and monitoring treatment response in MASH patients. • A reduction of 80ms in cT1, measured by Perspectum's LiverMultiScan, predicts histological response to MASH therapies, offering a non-invasive biomarker for clinical trials. • The studies highlight the potential of non-invasive tests (NITs) to track liver health changes, potentially reducing reliance on invasive liver biopsies in MASH drug development. • Perspectum's LiverMultiScan, an FDA-cleared technology, offers a comprehensive assessment of liver health by quantifying disease activity, severity, fat, and iron content.